Ouro Medicines

Ouro Medicines is a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases.

Health and bio

Acquired by GGilead Sciences on March 23, 2026 · MSN.

TIMELINE · MONEY RAISED

Ouro Medicines | 137 days from website to first raise on record

Raised $120M in 1 sourced round·1 signal before the first raise

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

1. March 23, 2026
   Acquired by GGilead Sciences
   Source: MSN
2. January 10, 2025
   Series A · $120M
   NNEA (lead), NNorwest Venture Partners (lead), TTPG (lead), BBoyu Capital, GGSK, LLongRiver Investments, MMonograph Capital, UUPMC Enterprises
   Source: fundraisingfox.com
3. August 26, 2024
   Website created

Founders and team

• JD
  Jaideep Dudani Founder

  LinkedIn
• CC
  Christina Carlson General Counsel and Chief Administrative Officer
• KB
  Kevin Baker Chief Development Officer
• NM
  Neely Mozaffarian CMO and Head of Development

Investors

• BBoyu Capital
• GGSK
• LLongRiver Investments
• MMonograph Capital
• NNEAlead investor
• NNorwest Venture Partnerslead investor
• TTPGlead investor
• UUPMC Enterprises

Companies like Ouro Medicines

• MMirador Therapeutics$250M Series B+ · Jan 2026
• HHI-Bio$95M Series B+ · Jan 2024
• KKhartis Therapeutics$95M Series B+ · Aug 2026
• EEngimmune Therapeutics$16M Seed · May 2022
• FFreya BiosciencesSeries A · Nov 2024
• SSudo Bio$37M Series A · Sep 2022

Other companies backed by NEA

• BBasalt Health$20M Series A · Oct 2026
• PPathos$237M Series B+ · Oct 2026
• TTamr$21M Series B+ · Oct 2026
• SSpiko Paris, France$90M Series B+ · Oct 2026
• AAutomating software development$200M Series B+ · Sep 2026
• PPositron$875M Series B+ · Sep 2026

NEA portfolio →